Akari Therapeutics (FRA:CLA) Ending Cash Position : €1.21 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Ending Cash Position?

Akari Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 was €1.21 Mil.

Akari Therapeutics's quarterly Ending Cash Position declined from Jun. 2023 (€6.63 Mil) to Dec. 2023 (€0.00 Mil) but then increased from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€1.21 Mil).

Akari Therapeutics's annual Ending Cash Position increased from Dec. 2021 (€8.28 Mil) to Dec. 2022 (€12.51 Mil) but then declined from Dec. 2022 (€12.51 Mil) to Dec. 2023 (€3.53 Mil).

Akari Therapeutics Ending Cash Position Historical Data

The historical data trend for Akari Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Ending Cash Position Chart

Akari Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

5.16

11.55

8.28

12.51

3.53

Akari Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															-	10.82	6.63	-	1.21

Akari Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Akari Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	12.151	+	-8.625
	=	3.53

Akari Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	3.537	+	-2.332
	=	1.21

Akari Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Akari Therapeutics (FRA:CLA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

AKTX:USA

Address

75/76 Wimpole Street, London, GBR, W1G 9RT

Website

https://www.akaritx.com

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.